

## Letter to the Editor

## Epilepsy in Leigh Syndrome Due To the ND3 Variant Requires Non-Mitochondrion-Toxic Anti-Seizure Drugs and the Ketogenic Diet

Josef Finsterer, MD, PhD\*

Neurological Department, Krankenanstalt Rudolfstiftung, Messerli Institute, Vienna, Austria

\*Corresponding Author  
Josef Finsterer, MD, PhD**Keywords:** epilepsy, mitochondrial, mtDNA, stroke-like lesion, multimodal MRI.

In a recent article Kori *et al.*, reported about a 4 years-old female with Leigh syndrome (LS) due to the ND3 variant m.10158T>C with a heteroplasmy rate of 82% (Kori, A. *et al.*, 2019). The study has a number of shortcomings, which require comments.

The first shortcoming is that the anti-seizure-therapy was inadequate. If only levetiracetam, carbamazepine and clobazam were given than it is not surprising that the patient deteriorated with recurrence of seizures and that cerebral lesions progressed. Seizures in patients with a mitochondrial disorder (MID) need to be aggressively treated as they may trigger stroke-like lesions (SLLs) and may become intractable (Finsterer, J., & Zarrouk, M. S. 2013). If three anti-seizure drugs (ASDs) are ineffective, they need to be replaced. When applying ASDs in MIDs only ASDs with a low mitochondrion-toxic potential should be used. ASDs with high mitochondrion-toxic potential include carbamazepine, valproic acid, phenytoin, and phenobarbital (Finsterer J. 2017). They should not be applied as first-line ASDs and only if less mitochondrion-toxic ASDs failed to be effective. If ASDs are ineffective, the ketogenic diet (KD) should be added as it may stop seizures (Paleologou, E. *et al.*, 2017). The KD attenuates neuronal injury via autophagy and other mitochondrial pathways (Wang, B. H. *et al.*, 2018).

The second shortcoming is that the nature of the cerebral lesions was not identified. Only T2- and T1-images were presented. More important would be

diffusion-weighted images, apparent-diffusion-coefficient maps, perfusion-weighted images, and the oxygen-extraction fraction MRI. Additionally, results of MR-spectroscopy should be presented. More profound assessment of the MRI may unmask the described lesions as SLLs, which require appropriate treatment with nitro-oxide-precursors, ASDs, steroids, or the KD.

We do not agree with the notion that there was a transition from LS to MELAS. Typical MRI features of LS were still present on the last MRI and SLLs may also occur in LS.

Overall, this interesting case report would be more meaningful if the entire ASD therapy and entire results of multimodal MRI was provided.

### REFERENCES

1. Kori, A., Hori, I., Tanaka, T., Aoyama, K., Ito, K., Hattori, A., ... & Saitoh, S. (2019). Transition from Leigh syndrome to MELAS syndrome in a patient with heteroplasmic MT-ND3 m. 10158T> C. Brain and Development. Finsterer, J., & Zarrouk, M. S. (2013). Mitochondrial epilepsy in pediatric and adult patients. *Acta Neurol Scand*, 128, 141-52.
2. Finsterer J. (2017). Toxicity of Antiepileptic Drugs to Mitochondria. *Handb Exp Pharmacol*, 240:473-88.
3. Paleologou, E., Ismayilova, N., & Kinali, M. (2017). Use of the Ketogenic Diet to Treat Intractable Epilepsy in Mitochondrial Disorders. *J Clin Med*, . pii: E56.

Quick Response Code



Journal homepage:

<http://www.easpublisher.com/easims/>

Article History

Received: 14.07.2019

Accepted: 29.07.2019

Published: 23.08.2019

Copyright © 2019: This is an open-access article distributed under the terms of the Creative Commons Attribution license which permits unrestricted use, distribution, and reproduction in any medium for non commercial use (NonCommercial, or CC-BY-NC) provided the original author and source are credited.

4. Wang, B. H., Hou, Q., Lu, Y. Q., Jia, M. M., Qiu, T., Wang, X. H., ... & Jiang, Y. (2018). Ketogenic diet attenuates neuronal injury via autophagy and mitochondrial pathways in pentylenetetrazol-kindled seizures. *Brain research*, 1678, 106-115.